A First in Human Study of PLT012 in Participants With Solid Tumor Cancers

NCT ID: NCT07337525

Last Updated: 2026-01-13

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-03-31
• Study Completion Date: 2028-01-31

Brief Summary

The goal of this clinical trial is to learn about what doses of PLT012 are safe to use in adults with advanced cancers in solid tumors. It will also learn about how effective different doses of PLT012 are in treating cancer. The main questions it aims to answer are:

What adverse events and toxicities (harmful side effects) are associated with different doses of PLT012? What are the blood levels of PLT012 in your body at different timepoints? What effect does PLT012 have on reducing tumor size and/or preventing the worsening of cancer? All participants will receive PLT012 and none will receive placebo (a look-alike substance that contains no drug).

Participants will receive PLT012 by intravenous infusion once every 3 weeks. Treatment with PLT012 can continue until the participant's disease worsens or they cannot tolerate treatment.

For the first 12 weeks, visits to the clinic will be more frequent (from 1 to 5 times over a 3-week period). After the first 12 weeks, visits will be reduced to once every 3 weeks.

Detailed Description

This study is a phase 1, open label, dose escalation study using an initial single participant cohort followed by a BOIN design to evaluate multiple ascending doses of PLT012.

Conditions

Advanced Malignant Solid Tumor; Solid Tumor Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Experimental Arm: PLT012

PLT012 administered via intravenous infusion once every 3 weeks

Group Type: EXPERIMENTAL

PLT012

Intervention Type: DRUG

PLT012 (anti-CD36 monoclonal antibody)

Interventions

PLT012

PLT012 (anti-CD36 monoclonal antibody)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Aged at least 18 years and provided written informed consent
• Histologically or cytologically confirmed advanced solid tumors (except primary CNS malignancies)
• Has at least one measurable lesion per RECIST v1.1
• ECOG PS of 0 to 1
• Life expectancy of ≥ 12 weeks
• Child-Pugh score of Class A (for hepatocellular carcinoma only)
• Adequate organ function as defined by protocol-specified laboratory values
• Not pregnant or breastfeeding

Exclusion Criteria

• Insufficient washout period from prior therapies as defined in the study protocol
• Ongoing Grade 2 or higher toxicities from prior treatments (with some exceptions)
• Concurrent or recent (within 2 years) malignancy other than the disease under study (with some exceptions)
• Uncontrolled HIV, uncontrolled hepatitis B, or uncontrolled acute hepatitis C infections
• Unstable/uncontrolled or untreated central nervous system (CNS) metastasis
• Active or recent (within 3 years) autoimmune disease requiring medical treatment
• Recipient of any organ transplant including allogeneic stem-cell transplant
• Clinically significant and active cardiovascular disease
• Known active alcohol or drug abuse
• Psychiatric disorders that would prohibit the understanding of the Informed Consent Form
• Ascites requiring therapeutic paracentesis or hepatic encephalopathy requiring medical interventions within the past 6 months (if hepatocellular carcinoma)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Pilatus Biosciences Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Anthony El-Khoueiry, MD

Role: PRINCIPAL_INVESTIGATOR

University of Southern California

Central Contacts

Novotech Project Manager

Role: CONTACT

Madison.Daniels@novotech-cro.com

+1 843 203 1031

Other Identifiers

PLT012-P1-001

Identifier Type: -

Identifier Source: org_study_id